Wuxi Biologics's Margin Pressure Looks Set to Linger -- Market Talk

WSJ03:44 ET

Wuxi Biologics Target Price Cut to HK$30 From HK$35.00 by Citi Research >2269.HK

Dow Jones03:12 ET

Wuxi Bio (02269): New projects exceed expectations, and the core logic of stable long-term development remains unchanged.

wuxi bio's fundamental outlook for stable long-term development remains unchanged

Zhitong Finance21:41 ET

[Brokerage Focus] Bocom Intl lowers the target price of Wuxi Bio (02269) by 24%, citing performance in line with expectations but short-term uncertainties still exist.

Jingu financial news | Bocom International released a research report stating that Wuxi Bio (02269) 1H24 revenue increased by 1.0% year-on-year, excluding the impact of the new crown, it grew by 7.7%, roughly in line with the company's previous guidance. Adjusted net income declined by 20.7% year-on-year. The company maintains its annual guidance: 1) full-year revenue and adjusted net income are expected to grow in the high single digits, benefiting from large payments and operational efficiency improvements, with the gross margin expected to improve sequentially in 2H; 2) full-year free cash flow turning positive, with capital expenditures of 4.8 billion yuan, expected annual capital expenditures of 5 billion yuan in 2025-26, focusing on expanding production capacity in Singapore. The bank notes that the company 1H24

金吾財訊20:48 ET

Wuxi Biologics' Margin Weakness May Persist -- Market Talk

WSJAug 22 04:39 ET

Wuxi Biologics Target Price Cut to HK$19.30 From HK$23.25 by Nomura >2269.HK

Dow JonesAug 22 03:53 ET